Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 15, 2021

BUY
$132.13 - $177.45 $9.25 Million - $12.4 Million
70,000 New
70,000 $12.4 Million
Q2 2021

Aug 16, 2021

SELL
$144.0 - $179.73 $13.6 Million - $17 Million
-94,500 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$158.92 - $221.61 $7.07 Million - $9.86 Million
44,500 Added 89.0%
94,500 $16.2 Million
Q4 2020

Feb 12, 2021

SELL
$162.05 - $240.27 $8.1 Million - $12 Million
-50,000 Reduced 50.0%
50,000 $11 Million
Q4 2019

Jan 31, 2020

BUY
$70.76 - $128.86 $7.08 Million - $12.9 Million
100,000 New
100,000 $12.9 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.